Vanguard Group’s TriSalus Life Sciences TLSI Stock Holding History

Vanguard Group’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$10.7M	Buy	1,530,707 +371,132	+32%	+$2.08M	﹤0.01%	2932
2025 Q3	$5.39M	Buy	1,159,575 +345,186	+42%	+$1.62M	﹤0.01%	3253
2025 Q2	$4.44M	Buy	814,389 +327,771	+67%	+$1.76M	﹤0.01%	3255
2025 Q1	$2.69M	Buy	486,618 +10,326	+2%	+$55K	﹤0.01%	3386
2024 Q4	$2.39M	Buy	476,292 +60,154	+14%	+$254K	﹤0.01%	3507
2024 Q3	$1.92M	Hold	416,138	–	–	﹤0.01%	3569
2024 Q2	$2.3M	Buy	416,138 +248,979	+149%	+$2.11M	﹤0.01%	3514
2024 Q1	$1.63M	Buy	167,159 +2,023	+1%	+$18.7K	﹤0.01%	3657
2023 Q4	$1.4M	Buy	+165,136	New	+$850K	﹤0.01%	3721

Other funds holding TLSI

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's TLSI Position: Q4 2025 in Review

Vanguard Group increased its TriSalus Life Sciences (TLSI) stake by 32% in Q4 2025, buying an estimated $2.08M and bringing the position to 1,530,707 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2932.

Vanguard Group first reported a position in TLSI in Q4 2023 and has held it in 9 quarters since. 67 funds tracked by Wall St. Rank hold TLSI as of Q4 2025.

Vanguard Group held 1,530,707 shares of TriSalus Life Sciences worth $10.7M as of Q4 2025.
Vanguard Group bought 371,132 TriSalus Life Sciences shares in Q4 2025, an estimated $2.08M.
TriSalus Life Sciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2932 holding.
Vanguard Group first reported a position in TriSalus Life Sciences in Q4 2023 and has held it in 9 quarters since.
67 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.